Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Lewis, Steven Kanner, Stanley Crooke, David Suhy

Premium

Arrowhead Research has named David Lewis as its new chief scientific officer.

Lewis most recently served as site head for the company's Madiscon, Wis., research and development facility, which Arrowhead acquired from Roche in 2011. Before that, he held various positions with Mirus Bio, which was acquired by Roche in 2007.

Arrowhead also said that Steven Kanner has joined the company as vice president of biology, taking over Lewis' former role. Previously, Kanner was vice president of discovery biology at Astek Pharmaceuticals.


Isis Pharmaceuticals announced that CEO and Chairman Stanley Crooke has been awarded the 2013 Director of the Year Award for Companies in Transition from the non-profit Corporate Directors Forum.


Bio-Matrix Scientific Group said that David Suhy has joined the scientific advisory board of its subsidiary Regen BioPharma.

Suhy is currently the vice president of research and development at Tacere Therapeutics, a subsidiary of Benitec Biopharma currently developing an expressed RNAi-based treatment for hepatitis C.

Regen recently took a license to Benitec's technology for use in developing a cancer vaccine.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more